Phase 3 studies of Trastuzumab used in patients with metastatic HER2+ breast cancer indicated the occurrence of serious AE such as cardiac dysfunction, dyspnea, asthenia, leukopenia, and infusion-related reactions (Piccart-Gebhart, M. et al., 2005). The gene discussed is ERBB2; the disease is breast carcinoma.